In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kura Oncology’s promising prospects. The recent expanded approval of a competitor’s drug, Revuforj, for treating a specific subset of AML patients, sets a positive precedent for Kura’s ziftomenib, which is awaiting potential approval. This approval is anticipated to occur by the end of November 2025, and it could significantly enhance Kura’s market position.
Furthermore, ziftomenib has demonstrated a favorable safety profile compared to Revuforj, with fewer instances of serious side effects such as QTc prolongations and differentiation syndrome. This safety advantage, coupled with comparable efficacy, suggests that ziftomenib could secure a more favorable label upon approval. The potential for ziftomenib to become a leading treatment option in a challenging AML subpopulation, along with Kura’s preparations for commercialization, underpins Pantginis’s optimistic outlook and Buy rating for the stock.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.